Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03531827
Title Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Enzalutamide + NLG207

Age Groups:
Covered Countries USA


No variant requirements are available.